| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
BRD7552 is an inducer of transcription factor PDX1, which increases insulin expression. In human cells, BRD7552 upregulated the expression of PDX1 via epigenetically altering PDX1 promoter area [3]. BRD7552 was discovered as a PDX1 inducer in a cell-based phenotypic screening assay. It was used to induce the expression of PDX1. In PANC-1 cells, BRD7552 up-regulated mRNA and protein levels of PDX1. BRD7552 changed epigenetic markers within the PDX1 promoter region that was consistent with transcriptional activation.
| ln Vitro |
After BRD7552 treatment in PANC-1 cells, PDX1 protein levels rise in a dose-dependent manner (0–5 μM; 5 days)[1]. In human ductal cells, BRD7552 increases PDX1 expression in a way that is dependent on FOXA2. Treatment of PANC-1 cells with BRD7552 (0-10 μM) for nine days results in a dose-dependent increase in the expression of insulin mRNA. In PANC-1 cells, BRD7552 stimulates the expression of insulin. BRD7552 exhibits H3 acetylation, H3K4me3, and H3K9me3 reductions, all of which are congruent with PDX1 transcriptional activation. Inducing epigenetic modifications that align with transcriptional activity, BRD7552 functions in a manner that is dependent on FOXA2[1].
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Cell Assay |
Western Blot Analysis[1]
Cell Types: PANC-1 cells Tested Concentrations: 1.25, 2.5, 5 μM Incubation Duration: 5 days Experimental Results: Induced a dose-dependent increase in PDX1 protein levels. |
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C33H33N3O15
|
|
|---|---|---|
| Molecular Weight |
711.63
|
|
| Exact Mass |
711.191
|
|
| CAS # |
1137359-47-7
|
|
| Related CAS # |
|
|
| PubChem CID |
23891512
|
|
| Appearance |
Typically exists as solid at room temperature
|
|
| Density |
1.5±0.1 g/cm3
|
|
| Boiling Point |
757.6±60.0 °C at 760 mmHg
|
|
| Flash Point |
412.0±32.9 °C
|
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
|
| Index of Refraction |
1.654
|
|
| LogP |
7.01
|
|
| Hydrogen Bond Donor Count |
4
|
|
| Hydrogen Bond Acceptor Count |
15
|
|
| Rotatable Bond Count |
14
|
|
| Heavy Atom Count |
51
|
|
| Complexity |
1200
|
|
| Defined Atom Stereocenter Count |
5
|
|
| SMILES |
O1[C@@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[H])OC(N([H])C1C([H])=C([H])C(C(=O)OC([H])([H])C([H])([H])[H])=C([H])C=1[H])=O)OC(N([H])C1C([H])=C([H])C2=C(C=1[H])OC([H])([H])O2)=O)OC(N([H])C1C([H])=C([H])C2=C(C=1[H])OC([H])([H])O2)=O)OC([H])([H])[H]
|
|
| InChi Key |
AAOLIMLEFKWKOY-IXMSMLDRSA-N
|
|
| InChi Code |
InChI=1S/C33H33N3O15/c1-3-43-29(38)17-4-6-18(7-5-17)34-31(39)49-26-25(14-37)48-30(42-2)28(51-33(41)36-20-9-11-22-24(13-20)47-16-45-22)27(26)50-32(40)35-19-8-10-21-23(12-19)46-15-44-21/h4-13,25-28,30,37H,3,14-16H2,1-2H3,(H,34,39)(H,35,40)(H,36,41)/t25-,26-,27+,28-,30+/m1/s1
|
|
| Chemical Name |
Methyl [2,3-O-bis(Benzo[1,3]dioxol-5-yl-carbamoyl)]-4-O-(4-ethoxycarbonyl-phenylcarbamoyl)-α-D-glucopyranoside
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4052 mL | 7.0261 mL | 14.0522 mL | |
| 5 mM | 0.2810 mL | 1.4052 mL | 2.8104 mL | |
| 10 mM | 0.1405 mL | 0.7026 mL | 1.4052 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA